Chronic Spontaneous Urticaria

Pediatric and adult chronic spontaneous urticaria exhibit distinct features, with adolescent presentations resembling those of adults more than those of younger children, according to a study published in Pediatric Allergy and Immunology.

SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The FDA has accepted for review the supplemental biologics license application for Dupixent for the treatment of chronic spontaneous urticaria, Regeneron Pharmaceuticals and Sanofi announced in a press release.

LOUISVILLE, Ky. — Patients assigned omalizumab for moderate to severe chronic spontaneous urticaria experienced superior time to clinically meaningful response compared with those on placebo, according to study results.

LOUISVILLE, Ky. — Dupilumab improved chronic spontaneous urticaria among patients whose disease did not respond to H1 antihistamines, according to a presentation here.

LOUISVILLE, Ky. — Patients with chronic spontaneous urticaria experienced improvements with dupilumab, according to a study presented at the American College of Asthma & Immunology Annual Scientific Meeting.

Remibrutinib appeared very effective in treating moderate to severe chronic spontaneous urticaria, with a rapid onset of action and a favorable safety profile, according to a study published in The Journal of Allergy & Clinical Immunology.

For allergists interested in dermatology-focused findings from the European Academy of Dermatology and Venereology Congress but who could not attend the meeting this year in Milan, Healio presents this list of seven studies that may be relevant to your practice.

MILAN — Remibrutinib reduced the need for second-generation H1 antihistamines as a rescue medication in patients with chronic spontaneous urticaria across all doses in a 12-week study.